Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18267069 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Wajapeyee N, et al. (2008) Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132, 363-74 18267069
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T202-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  SK-MEL28 (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGFBP-7 decrease
siRNA IGFBP-7 RKIP (human) inhibit treatment-induced decrease
GW 5074 decrease
PD98059 decrease
BRAF (human) decrease V600E mutant
siRNA IGFBP7 (human) BRAF (human) inhibit treatment-induced decrease
BRAF (human) inhibit treatment-induced decrease anti-IGFBP7 antibody
serum increase
IGFBP-7 serum inhibit treatment-induced increase

Y204-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  SK-MEL28 (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGFBP-7 decrease
siRNA IGFBP-7 RKIP (human) inhibit treatment-induced decrease
GW 5074 decrease
PD98059 decrease
BRAF (human) decrease V600E mutant
siRNA IGFBP7 (human) BRAF (human) inhibit treatment-induced decrease
BRAF (human) inhibit treatment-induced decrease anti-IGFBP7 antibody
serum increase
IGFBP-7 serum inhibit treatment-induced increase

T185-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  SK-MEL28 (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGFBP-7 decrease
siRNA IGFBP-7 RKIP (human) inhibit treatment-induced decrease
GW 5074 decrease
PD98059 decrease
BRAF (human) decrease V600E mutant
siRNA IGFBP7 (human) BRAF (human) inhibit treatment-induced decrease
BRAF (human) inhibit treatment-induced decrease anti-IGFBP7 antibody
serum increase
IGFBP-7 serum inhibit treatment-induced increase

Y187-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  melanoma skin cancer
 Relevant cell lines - cell types - tissues:  SK-MEL28 (melanocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IGFBP-7 decrease
siRNA IGFBP-7 RKIP (human) inhibit treatment-induced decrease
GW 5074 decrease
PD98059 decrease
BRAF (human) decrease V600E mutant
siRNA IGFBP7 (human) BRAF (human) inhibit treatment-induced decrease
BRAF (human) inhibit treatment-induced decrease anti-IGFBP7 antibody
serum increase
IGFBP-7 serum inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.